Drugmaker Pulls Third-Line PARP Inhibitor Approval in Ovarian Cancer
Clovis Oncology has voluntarily withdrawn the indication for rucaparib (Rubraca) as a third-line treatment in BRCA-mutated ovarian cancer after an overall survival (OS) analysis showed a signal for potential harm, according to a filing with the Securities and Exchange Commission (SEC). “Based on further discussions with the FDA following submission of ARIEL4 OS data previously […]